Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
MetrioPharm
MetrioPharm
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Rentschler Biopharma appoints Patrick Cushing as VP Operations for US subsidiary
The novel position will require Dr Cushing to manager operations at the Miford, MA facility in the US
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Johnson & Johnson submits regulatory application for Tremfya to the European Medicines Agency
The submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn’s disease, which each achieved their primary...
Amolyt receives FDA fast track designation for hypoparathyroidism drug
The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Finance
European Commission funds MetrioPharm COVID project
Project iMPact will receive funding under the HERA incubator
Research & Development
Long-term toxicology studies confirm MP1032 safety profile
MetrioPharm's lead compound has been evaluated in dogs and rats, confirming its "very good tolerability"
Subscribe now